U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06895733) titled 'Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)' on March 18.
Brief Summary: The efficacy and safety of Pazopanib combined with Palbociclib in the third line and above treatment of refractory solid tumors co amplified in the 11q13 region (FGF3/4/19/CCND1).
Study Start Date: Nov. 27, 2024
Study Type: INTERVENTIONAL
Condition:
Solid Tumor, Adult
Next-generation Sequencing
Precision Medicine
Intervention:
DRUG: Pazopanib Oral Tablet
Orally administered once daily (100mg)for 21 consecutive days, followed by a 7-day cessation of medication; Every 28 days is ...